Rituximab as first line: an advent in pemphigus

MLA

V. P. K. Gopinath, et al. “Rituximab as First Line: An Advent in Pemphigus.” International Journal of Research in Dermatology, vol. 5, Jan. 2019, p. 212. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6fff6da6042bf2226c39315b911afd10&authtype=sso&custid=ns315887.

APA

V. P. K. Gopinath, Tresy Jose, Basheer Ahammed Kolaparambath, V. M. Simi, P. M. Farisa, & C. M. Ali Rishad. (2019). Rituximab as first line: an advent in pemphigus. International Journal of Research in Dermatology, 5, 212.

Chicago

V. P. K. Gopinath, Tresy Jose, Basheer Ahammed Kolaparambath, V. M. Simi, P. M. Farisa, and C. M. Ali Rishad. 2019. “Rituximab as First Line: An Advent in Pemphigus.” International Journal of Research in Dermatology 5 (January): 212. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6fff6da6042bf2226c39315b911afd10&authtype=sso&custid=ns315887.